You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK):潛在全球同類最佳藥物CS5001(ROR1ADC)全球多中心I期臨牀研究完成中國首例患者入組
格隆匯 04-24 08:09

格隆匯4月24日丨基石藥業-B(02616.HK)發佈公吿,正在美國和澳洲進行I期臨牀研究的潛在同類最佳藥物CS5001用於治療晚期實體瘤和淋巴瘤的國際多中心I期臨牀研究CS5001-101日前在中國完成首例患者入組。

根據披露,CS5001的全球多中心I期臨牀研究已在美國和澳洲完成多個劑量組的評估,並展現了良好的安全性和耐受性。中國研究中心的加入進一步加速潛在全球同類最佳藥物CS5001的全球同步開發。作為全球研發最快的受體酪氨酸激酶樣孤兒受體1(receptor tyrosine kinase-like orphan receptor 1,“ROR1”)抗體偶聯藥物(“ADC”)之一,CS5001已在轉化醫學研究中展示了其在多種惡性血液和實體腫瘤的治療潛力。這是基石藥業正在推進的管線2.0戰略的又一里程碑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account